Business updates for various pharma and life science companies around the globe.
Treatment with Stelara is resulting in positive outcomes for patients with Crohn’s disease, as Janssen Pharmaceutical said 79% of patients in a late-stage trial showed a clinical response to the medication and 67% were in clinical remission.
Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
The Nasdaq indicated that there was a record amount of biotech initial public offerings (IPOs) in 2018, totaling around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new three-year data from the IM-UNITI study, which demonstrates the continued efficacy of Stelara (ustekinumab) in improving clinical remission rates and shows the drug to be generally well-tolerated in patients with Crohn’s disease.
Two years after forging a partnership to collaborate on microbiome targets for gastrointestinal disorders, France-based Enterome and Japan’s Takeda Pharmaceutical have entered into a second agreement, this time with a specific focus on Crohn’s disease.
Shares of South Korea-based Celltrion were down more than 5 percent after the company announced it received a warning letter from the U.S. Food and Drug Administration after the regulatory agency inspected a company drug manufacturing facility.
Shares of Belgium-based TiGenix NV shot up after Japan’s Takeda Pharmaceutical opted to acquire the company for $630 million.
The U.S. Food and Drug Administration approved Pfizer Inc.’s second biosimilar to Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade.
Celgene is scrapping a late-stage Crohn’s disease drug it acquired in a $710 million deal three years ago following an interim data analysis.